{
    "clinical_study": {
        "@rank": "65540", 
        "arm_group": {
            "arm_group_label": "SERI\u00ae scaffold implanted breasts", 
            "arm_group_type": "Experimental", 
            "description": "Revision augmentation of the breast with adjunctive SERI\u00ae surgical scaffold"
        }, 
        "brief_summary": {
            "textblock": "An evaluation of the clinical performance of SERI\u00ae Surgical Scaffold for soft tissue support\n      in subjects undergoing revision augmentation surgery for increased nipple to inframammary\n      fold distance."
        }, 
        "brief_title": "SERI\u00ae Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Subjects Requiring Revision Breast Augmentation Surgery", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Negative nicotine test at screening visit\n\n          -  Previous augmentation with silicone-filled or saline-filled breast implants requiring\n             Revision Augmentation surgery for increased nipple:inframmary fold distance\n\n          -  Well vascularized skin flaps that can be approximated without tension\n\n        Exclusion Criteria:\n\n          -  BMI (Body Mass Index) that is \u2265 30 kg/m2\n\n          -  Active smoker or have smoked within 6 weeks prior to screening visit\n\n          -  Pregnant or nursing\n\n          -  Advanced fibrocystic disease considered to be premalignant without accompanying\n             subcutaneous mastectomy\n\n          -  Carcinoma of the breast\n\n          -  Previous mastectomy or lumpectomy\n\n          -  Abscess or infection in the body at the time of enrollment\n\n          -  Had any disease, including uncontrolled diabetes (e.g., HbAIc > 8%), that is\n             clinically known to impact wound healing ability. For example: collagen-vascular,\n             connective tissue or autoimmune disorders (e.g., Systemic Lupus, Rheumatoid\n             Arthritis, Scleroderma)\n\n          -  Subjects with diagnosed diabetes must have HbAIc \u2264 8% within 3 months of enrollment\n\n          -  Showed tissue characteristics that were clinically incompatible with mammaplasty,\n             such as tissue damage resulting from radiation, inadequate tissue, compromised\n             vascularity or ulceration\n\n          -  Had, or was under treatment for, any condition that may have constituted an\n             unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)\n\n          -  History of prior implantation of any surgical scaffold (e.g., synthetic mesh,\n             acellular dermal matrix, or biologic mesh) in the breast\n\n          -  Implantation of any non-SERI\u00ae surgical scaffold (e.g., synthetic mesh, acellular\n             dermal matrix, or biologic mesh) during the study period\n\n          -  Product contraindications for use of SERI\u00ae Surgical Scaffold per the supplied package\n             insert (e.g., hypersensitivity to silk)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030938", 
            "org_study_id": "GMA-SERI-13-001"
        }, 
        "intervention": {
            "arm_group_label": "SERI\u00ae scaffold implanted breasts", 
            "description": "Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI\u00ae Surgical Scaffold placed intra- or extra-capsularly.", 
            "intervention_name": "SERI\u00ae Surgical Scaffold", 
            "intervention_type": "Device", 
            "other_name": "SERI\u00ae Surgical Scaffold"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "breast implant", 
            "revision augmentation", 
            "stretch deformity", 
            "fold malposition", 
            "bottoming out"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Troy", 
                    "country": "United States", 
                    "state": "Michigan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "SERI\u00ae Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery", 
        "overall_contact": {
            "email": "devicetrials@allergan.com", 
            "last_name": "Allergan Medical"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This refers to the proportion of implanted breasts that will require reoperation for the recurrence of the initial cause of the increase in nipple to inframammary fold distance at the end of the 12-month follow-up period.", 
            "measure": "Reoperation rate (per implanted breast) for the presenting condition at 12 months.", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}